These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 17660718)

  • 41. Neisseria meningitidis serogroup B vaccine development.
    Caesar NM; Myers KA; Fan X
    Microb Pathog; 2013 Apr; 57():33-40. PubMed ID: 23416222
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevention of group B meningococcal disease by vaccination: a difficult task.
    Thomas M
    N Z Med J; 2004 Aug; 117(1200):U1016. PubMed ID: 15475986
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MeNZB vaccine and epidemic control: when do you stop vaccinating?
    Loring BJ; Turner N; Petousis-Harris H
    Vaccine; 2008 Nov; 26(47):5899-904. PubMed ID: 18804134
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB).
    Bettinger JA; Scheifele DW; Halperin SA; Vaudry W; Findlow J; Borrow R; Medini D; Tsang R;
    Vaccine; 2013 Dec; 32(1):124-30. PubMed ID: 23588089
    [TBL] [Abstract][Full Text] [Related]  

  • 45. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.
    Perez JL; Absalon J; Beeslaar J; Balmer P; Jansen KU; Jones TR; Harris S; York LJ; Jiang Q; Radley D; Anderson AS; Crowther G; Eiden JJ
    Expert Rev Vaccines; 2018 Jun; 17(6):461-477. PubMed ID: 29883226
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Re: Safety review: Two outer membrane vesicle (OMV) vaccines against systemic Neisseria meningitidis serogroup B disease, Nokleby H, Aavitsland P, O'Hallahan J, Feiring B, Tilman S, Oster P. Vaccine 2007;25(16):3080-4.
    Lennon D
    Vaccine; 2007 Sep; 25(39-40):6833; author reply 6833-4. PubMed ID: 17630051
    [No Abstract]   [Full Text] [Related]  

  • 47. Evaluation of meningitis surveillance before introduction of serogroup a meningococcal conjugate vaccine - Burkina Faso and Mali.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1025-8. PubMed ID: 23254257
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The strategy to control New Zealand's epidemic of group B meningococcal disease.
    O'Hallahan J; Lennon D; Oster P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S293-8. PubMed ID: 15597072
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Estimating primary care attendance rates for fever in infants after meningococcal B vaccination in England using national syndromic surveillance data.
    Harcourt S; Morbey RA; Bates C; Carter H; Ladhani SN; de Lusignan S; Smith GE; Elliot AJ
    Vaccine; 2018 Jan; 36(4):565-571. PubMed ID: 29246475
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Emerging experience with meningococcal serogroup B protein vaccines.
    Toneatto D; Pizza M; Masignani V; Rappuoli R
    Expert Rev Vaccines; 2017 May; 16(5):433-451. PubMed ID: 28375029
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
    Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
    Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic.
    Aaberge IS; Oster P; Helland OS; Kristoffersen AC; Ypma E; Høiby EA; Feiring B; Nøkleby H
    Clin Diagn Lab Immunol; 2005 May; 12(5):599-605. PubMed ID: 15879021
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Intensive Vaccines Monitoring Programme (IVMP): an electronic system to monitor vaccine safety in New Zealand.
    Tatley MV; Kunac DL; McNicholas A; Zhou L; Ballantyne S; Ashton J; Stehr-Green P; Galloway Y; Reid S
    Vaccine; 2008 May; 26(22):2746-52. PubMed ID: 18430496
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study.
    Perrett KP; McVernon J; Richmond PC; Marshall H; Nissen M; August A; Percell S; Toneatto D; Nolan T
    Vaccine; 2015 Sep; 33(39):5217-24. PubMed ID: 26232542
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Meningococcal B vaccine (4CMenB): the journey from research to real world experience.
    Rappuoli R; Pizza M; Masignani V; Vadivelu K
    Expert Rev Vaccines; 2018 Dec; 17(12):1111-1121. PubMed ID: 30457407
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.
    Zlotnick GW; Jones TR; Liberator P; Hao L; Harris S; McNeil LK; Zhu D; Perez J; Eiden J; Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2015; 11(1):5-13. PubMed ID: 25483509
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.
    Pezzotti P; Miglietta A; Neri A; Fazio C; Vacca P; Voller F; Rezza G; Stefanelli P
    Vaccine; 2018 Jul; 36(29):4222-4227. PubMed ID: 29895504
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Quadrivalent meningococcal conjugate vaccines.
    Pace D; Pollard AJ; Messonier NE
    Vaccine; 2009 Jun; 27 Suppl 2():B30-41. PubMed ID: 19477560
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Vaccinal strategies in response to new epidemiological challenges in 2010. Reasonable hope for a "B" meningococcal vaccine].
    Nicolas P
    Med Trop (Mars); 2010 Aug; 70(4):325-32. PubMed ID: 22368926
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A phase 1 study of a group B meningococcal native outer membrane vesicle vaccine made from a strain with deleted lpxL2 and synX and stable expression of opcA.
    Keiser PB; Gibbs BT; Coster TS; Moran EE; Stoddard MB; Labrie JE; Schmiel DH; Pinto V; Chen P; Zollinger WD
    Vaccine; 2010 Oct; 28(43):6970-6. PubMed ID: 20732470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.